Simon Bennett
Corporate Officer/Principal bei AVACTA GROUP PLC
Profil
Simon Bennett is currently the Chief Business Officer-Therapeutics Division at Avacta Group Plc since 2023.
Prior to this, he held the position of Director-Business Development at Oxagen Ltd., Solexa Ltd., and MedPharm Ltd.
He also served as Vice President-Business Development at Glide Pharmaceutical Technologies Ltd.
Aktive Positionen von Simon Bennett
Unternehmen | Position | Beginn |
---|---|---|
AVACTA GROUP PLC | Corporate Officer/Principal | 19.12.2023 |
Ehemalige bekannte Positionen von Simon Bennett
Unternehmen | Position | Ende |
---|---|---|
Oxagen Ltd.
Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
MedPharm Ltd.
MedPharm Ltd. Pharmaceuticals: MajorHealth Technology MedPharm Ltd. provides pharmaceutical research and development services for dermatological, nail, eye, airway, mucosal membrane, and transdermal products. Its drug delivery technologies include MedSpray, a patch-in-a-can aerosol technology for drug delivery in the form of a film to topical/mucosal membranes for immediate or sustained/extended delivery. The company was founded by Andrew G. Muddle in August 1999 and is headquartered in Guildford, the United Kingdom. | Corporate Officer/Principal | - |
Solexa Ltd.
Solexa Ltd. Medical SpecialtiesHealth Technology Solexa Ltd. was a developer of instruments for analyzing genes in the process of drug development. It's research methods have included DNA sequencing, gene expression, genotyping and micro-RNA analysis to allow scientists to analyze individual genomes for drug development and personalized medicine. The company was headquartered in Saffron Walden, UK. | Corporate Officer/Principal | - |
Glide Pharmaceutical Technologies Ltd.
Glide Pharmaceutical Technologies Ltd. Pharmaceuticals: MajorHealth Technology Glide Pharmaceutical Technologies Ltd. developed and manufactured pharmaceutical products. The firm developed SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. It also engaged in developing a non-invasive diagnostic technology that primarily focuses on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker. The company was founded by Charles David Ogilvy Potter on 6th March, 2001 and was headquartered in Abingdon, the United Kingdom. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AVACTA GROUP PLC | Commercial Services |
Private Unternehmen | 4 |
---|---|
Glide Pharmaceutical Technologies Ltd.
Glide Pharmaceutical Technologies Ltd. Pharmaceuticals: MajorHealth Technology Glide Pharmaceutical Technologies Ltd. developed and manufactured pharmaceutical products. The firm developed SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. It also engaged in developing a non-invasive diagnostic technology that primarily focuses on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker. The company was founded by Charles David Ogilvy Potter on 6th March, 2001 and was headquartered in Abingdon, the United Kingdom. | Health Technology |
MedPharm Ltd.
MedPharm Ltd. Pharmaceuticals: MajorHealth Technology MedPharm Ltd. provides pharmaceutical research and development services for dermatological, nail, eye, airway, mucosal membrane, and transdermal products. Its drug delivery technologies include MedSpray, a patch-in-a-can aerosol technology for drug delivery in the form of a film to topical/mucosal membranes for immediate or sustained/extended delivery. The company was founded by Andrew G. Muddle in August 1999 and is headquartered in Guildford, the United Kingdom. | Health Technology |
Solexa Ltd.
Solexa Ltd. Medical SpecialtiesHealth Technology Solexa Ltd. was a developer of instruments for analyzing genes in the process of drug development. It's research methods have included DNA sequencing, gene expression, genotyping and micro-RNA analysis to allow scientists to analyze individual genomes for drug development and personalized medicine. The company was headquartered in Saffron Walden, UK. | Health Technology |
Oxagen Ltd.
Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Health Technology |